B-cell subsets, signaling and their roles in secretion of autoantibodies. (July 2016)

• Record Type: Journal Article
• Authors: Iwata, S; Tanaka, Y
• Is Part Of: Lupus. Volume 25:Number 8(2016)
• Page Start: 850
• Page End: 856
• Publication Date: 2016-07
• Subjects: SLE -- B cell -- Syk -- Btk -- JAK; Systemic lupus erythematosus -- Periodicals; 616.772005
• DOI: 10.1177/0961203316643172
• Languages: English
• ISSNs: 0961-2033

Abstract

B cells play a pivotal role in the pathogenesis of autoimmune diseases. In patients with systemic lupus erythematosus (SLE), the percentages of plasmablasts and IgD − CD27 − double-negative memory B cells in peripheral blood are significantly increased, while IgD + CD27 + IgM memory B cells are significantly decreased compared to healthy donors. The phenotypic change is significantly associated with disease activity and concentration of autoantibodies. Treatment of B-cell depletion using rituximab results in the reconstitution of peripheral B cells in SLE patients with subsequent improvement in disease activity. Numerous studies have described abnormalities in B-cell receptor (BCR)-mediated signaling in B cells of SLE patients. Since differences in BCR signaling are considered to dictate the survival or death of naïve and memory B cells, aberrant BCR signal can lead to abnormality of B-cell subsets in SLE patients. Although Syk and Btk function as key molecules in BCR signaling, their pathological role in SLE remains unclear. We found that Syk and Btk do not only transduce activation signal through BCR, but also mediate crosstalk between BCR and Toll-like receptor (TLR) as well as BCR and JAK-STAT pathways in human B cells in vitro. In addition, pronounced Syk and Btk phosphorylation was observed in B cells of patients with active SLE compared to those of healthy individuals. The results suggest the involvement of Syk and Btk activation in abnormalities of BCR-mediated signaling and B-cell phenotypes during the pathological process of SLE and that Syk, Btk and JAK are potential therapeutic targets in SLE.